<DOC>
	<DOC>NCT00405184</DOC>
	<brief_summary>This study aims to assess the safety, tolerability and pharmacokinetics of Ig NextGen 10% in patients with primary immune deficiency currently being treated with Intragam P. Eligible patients will switch from 3 to 4 weekly intravenous Intragam P therapy to receive seven cycles of Ig NextGen 10% treatment administered intravenously at three- to four-weekly intervals. Patients will be monitored on the study for up to 36 weeks.</brief_summary>
	<brief_title>Ig NextGen 10% in Patients With Primary Immune Deficiency (PID)</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<criteria>Clinical diagnosis of PID = or &gt;6 month use of Intragam P at three or fourweekly intervals = or &gt;6 month history of IgG trough levels of â‰¥ 5 g/L Newly diagnosed PID within six months prior to Screening Known selective IgA deficiency or antibodies to IgA Immunosuppressive treatment other than topical and/ or inhaled steroids and/ or low dose oral steroids Proteinlosing enteropathies, or kidney diseases History of malignancies of lymphoid cells Any of the following laboratory results at Screening: Serum Creatinine &gt; 1.5 times the upper normal limit (UNL) AST or ALT concentration &gt; 2.5 times the UNL Albumin &lt; 25 g/L</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>PID</keyword>
	<keyword>IVIg</keyword>
	<keyword>IntragamP</keyword>
</DOC>